1-benzyl-4-o-tolyl-pyrrolidine-3-carboxylic acid | 874990-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-benzyl-4-o-tolyl-pyrrolidine-3-carboxylic acid
• 英文别名: 1-benzyl-4-(2-methylphenyl)pyrrolidin-1-ium-3-carboxylate
• CAS: 874990-41-7
• 化学式: C₁₉H₂₁NO₂
• 分子量: 295.381
• InChiKey: SRTWLLSJNUBXOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-o-tolyl-pyrrolidine-3-carboxylic acid 、 卡特缩合剂 、 N,N-二异丙基乙胺 、 2-苄基吡咯烷 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-Benzyl-3-[(2-benzylpyrrolidin-1-yl)carbonyl]-4-(2-methylphenyl)pyrrolidine
  参考文献：
  名称：

  3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

  摘要：

  本发明涉及式(I)的3,4-取代吡咯烷化合物，其是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。

  公开号：

  US08354545B2
• 作为产物：
  描述：

  1-Benzyl-4-(2-methylphenyl)pyrrolidine-3-carboxylate 、 sodium hydroxide 、 盐酸 在 crude acid 、 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 Methanol tetrahydrofuran water 为溶剂， 反应 12.0h， 生成 1-benzyl-4-o-tolyl-pyrrolidine-3-carboxylic acid
  参考文献：
  名称：

  3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

  摘要：

  本发明涉及式(I)的3,4-取代吡咯烷化合物，其是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。

  公开号：

  US08354545B2

文献信息

• Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
  申请人：Bennani L. Youssef

  公开号：US20060025601A1

  公开（公告）日：2006-02-02

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明一般涉及一系列化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为治疗剂的使用。更具体地，本发明的化合物是三环茚并吡咯化合物。这些化合物是血清素受体（5-HT）的配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、障碍和状况（例如焦虑、抑郁和肥胖）。
• [EN] 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE PYRROLIDINES 3,4-SUBSTITUÉES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2009078932A1

  公开（公告）日：2009-06-25

  The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的3,4-取代吡咯烷化合物，其为β-分泌酶酶抑制剂，可用于治疗涉及β-分泌酶酶的疾病，如阿尔茨海默病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗涉及β-分泌酶酶的疾病中的用途。
• TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS
  申请人：Bennani Youssef L.

  公开号：US20090239925A1

  公开（公告）日：2009-09-24

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明通常涉及一系列化合物，包括含有这些化合物的药物组合物，以及将这些化合物和组合物用作治疗剂。更具体地说，本发明的化合物是三环吲哚-吡咯化合物。这些化合物是血清素受体（5-HT）配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、障碍和病状（例如焦虑、抑郁和肥胖症）。
• 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Stachel Shawn J.

  公开号：US20100280009A1

  公开（公告）日：2010-11-04

  The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及公式（I）的3,4-取代吡咯烷化合物，其为β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，例如阿尔茨海默病中有用。本发明还涉及包含这些化合物的药物组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators
  申请人：Bennani Youssef L.

  公开号：US20110172283A1

  公开（公告）日：2011-07-14

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明通常涉及一系列化合物，含有这些化合物的制药组合物，以及将这些化合物和组合物用作治疗剂的用途。更具体地说，本发明的化合物是三环吲哚-吡咯化合物。这些化合物是血清素受体（5-HT）配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、疾病和病情（例如焦虑、抑郁和肥胖症）。